Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: J Neuroimmunol. 2013 Jun 12;262(0):11–18. doi: 10.1016/j.jneuroim.2013.05.012

Figure 3. BDNF expression increases at EAE onset, while soluble type I NRG1 increases in chronic disease.

Figure 3

C57BL/6 mice were immunized with MOG35-55(200μg)/CFA containing M. Tbc (1mg/ml)/PT(200X2 ng), and were scored daily for disease. The mean score of EAE is shown (A). On the indicated day after immunization (onset day 12-15 or chronic phase day 35), brain tissues were collected from individual mice. RNA isolation and qPCR were performed from individual brain samples as described in the Methods. Each bar represents an individual mouse with indicated clinical score and the fold change in mRNA expression of types I (B) and III NRG1 (C), BDNF (D) and GDNF (E) at disease onset or chronic stage versus the average of the gene expression in naïve mice (n=4). Compared to naive mice (n=4), BDNF increased at disease onset and type I NRG1 expression increased in chronic stages (day 35 post-immunization). The samples were considered to show little change if the fold changes were less than 1.5 or were variable within the same group.